Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.

BACKGROUND

Heavy menstrual bleeding occurs in 80% of women with von Willebrand disease and is associated with iron deficiency and poor response to current therapies. International guidelines indicate low certainty regarding effectiveness of hormonal therapy and tranexamic acid. Although von Willebrand factor (VWF) concentrate is approved for bleeds, no prospective trials guide its use in heavy menstrual bleeding. We aimed to compare recombinant VWF with tranexamic acid for reducing heavy menstrual bleeding in patients with von Willebrand disease.

METHODS

VWDMin, a phase 3, open-label, randomised crossover trial, was done in 13 haemophilia treatment centres in the USA. Female patients aged 13-45 years with mild or moderate von Willebrand disease, defined as VWF ristocetin cofactor less than 0·50 IU/mL, and heavy menstrual bleeding, defined as a pictorial blood assessment chart (PBAC) score more than 100 in one of the past two cycles were eligible for enrolment. Participants were randomly assigned (1:1) to two consecutive cycles each of intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1, and oral tranexamic acid 1300 mg three times daily on days 1-5, the order determined by randomisation. The primary outcome was a 40-point reduction in PBAC score by day 5 after two cycles of treatment. Efficacy and safety were analysed in all patients with any post-baseline PBAC scores. The trial was stopped early due to slow recruitment on Feb 15, 2022, by a data safety monitoring board request, and was registered at ClinicalTrials.gov, NCT02606045.

FINDINGS

Between Feb 12, 2019, and Nov 16, 2021, 39 patients were enrolled, 36 of whom completed the trial (17 received recombinant VWF then tranexamic acid and 19 received tranexamic acid then recombinant VWF). At the time of this unplanned interim analysis (data cutoff Jan 27, 2022), median follow-up was 23·97 weeks (IQR 21·81-28·14). The primary endpoint was not met, neither treatment corrected PBAC score to the normal range. Median PBAC score was significantly lower after two cycles with tranexamic acid than with recombinant VWF (146 [95% CI 117-199] vs 213 [152-298]; adjusted mean treatment difference 46 [95% CI 2-90]; p=0·039). There were no serious adverse events or treatment-related deaths and no grade 3-4 adverse events. The most common grade 1-2 adverse events were mucosal bleeding (four [6%] patients during tranexamic acid treatment vs zero during recombinant VWF treatment) and other bleeding (four [6%] vs two [3%]).

INTERPRETATION

These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease. These findings support discussion of treatment options for heavy menstrual bleeding with patients based on their preferences and lived experience.

FUNDING

National Heart Lung Blood Institute (National Institutes of Health).

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests MVR reports research funding to her institution from BioMarin, Sanofi, SPARK, and Takeda Pharmaceuticals; and service on advisory boards of BeBio, BioMarin, Hemab Therapeutics, Sanofi, SPARK, and Takeda Pharmaceuticals. DN reports research funding from Bayer; service on advisory boards for Alnylam, Aptevo, Bioverativ, Genentech, Octapharma; and service on speaker's bureaus for Octopharma, American Porphyria Foundation, BPL/Soleo Health, and Alnylam. ADL reports research funding from BioMarin and Pfizer; and service on advisory boards for BioMarin, CSL, Dova, and Pfizer. RSJ reports research funding from Takeda and Octapharma; and consulting with Sanofi/Sobi, Takeda, Octapharma, NovoNordisk, Bayer, Pfizer, Hema Biologics, Guardian Therapeutics, and Hemab Therapeutics. CP serves on advisory boards for Takeda, Hema Biologics, and Coagulant Therapeutics. RP receives honoraria from CSL Behring, Genentech, Bayer Healthcare, Hema Biologics, Instrumentation Laboratory, and Merck. APW serves on advisory boards of NovoNordisk, Hema Biologics, Takeda, Sanofi, Genentech, Octapharma, Pfizer, Bioverativ, Bayer, and Spark. RK serves on advisory boards of CSL Behring, Sanofi, NovoNordisk, and Pfizer. CS serves as a consultant to Genentech, Hema Biologics, Novo Nordisk, and Takeda. KJS reports research funding from Sanofi Pasteur. TCN reports research funding from Pfizer and Spark. ADA is currently an employee of Medtronic. All other authors declare no competing interests.